Latest Headlines

  1. Overture Life Launches Global ICSI.A Center Of Excellence Program, Bringing The World's First Automated ICSI Into Clinical Use Across Five Leading Global Fertility Centers 6/25/2026

    Overture Life, the global leader in automated IVF and the first company to achieve live births from both robotic fertilization and robotic egg freezing, announced the launch of its ICSI.A Center of Excellence Program, with the first clinical deployments of the world's first automated intracytoplasmic sperm injection (ICSI) workstation at five leading fertility centers: CERAS in Peru, Memorial Hospital in Turkey, CENALFES in Bolivia, Seoul IVF in South Korea, and Procrearte in Argentina.

  2. Ultra-High Precision Optical Flats 6/25/2026

    Optical Surfaces Ltd. is a leading supplier of ultra-high precision optical flats to research establishments and national standards laboratories worldwide.

  3. Verici Dx Receives New York State Approval, Establishing Nationwide Access To Tutivia Kidney Transplant Rejection Test 6/24/2026

    Verici Dx plc, a developer of advanced clinical diagnostics for organ transplant, today announced it has received clinical laboratory accreditation from the New York State Department of Health (NYSDOH) Clinical Laboratory Evaluation Program (CLEP).

  4. StatLab Launches CytoPath Disc, Advancing Standardized Cell Block Preparation Worldwide 6/24/2026

    StatLab Medical Products, a leading global developer and manufacturer of pathology supplies and equipment, today announced the global launch of the CytoPath Disc, an innovative cell block preparation technology designed to standardize and simplify cell block preparation.

  5. Tecan Accelerates Data-Driven Lab Journey With Agentic AI Developments Powered By NVIDIA 6/24/2026

    Tecan, a global provider of laboratory automation and solutions, today announced the integration of Agentic AI capabilities into its lab analytics platform Introspect, leveraging NVIDIA BioNeMo Agent Toolkit.

  6. Versant Diagnostics Expands Collaboration With Leica Biosystems As PRW Laboratories Becomes First To Deploy Aperio GT Elite Solution 6/24/2026

    Leica Biosystems, a Danaher company and a global leader in end-to-end anatomic and digital pathology solutions, and Versant Diagnostics, an independent physician services company actively engaged in next-generation digital pathology, announce an expanded collaboration to advance digital pathology adoption.

  7. Legacy Receives New York State CLEP Approval For Two Laboratory-Developed Tests: Semen Analysis And DNA Fragmentation 6/24/2026

    Legacy, a leading male fertility testing and sperm preservation company, today announced that the New York State Department of Health's Clinical Laboratory Evaluation Program (CLEP), administered by the Wadsworth Center, has validated and approved two of its laboratory-developed tests: semen analysis and sperm DNA fragmentation analysis.

  8. ALZpath Signs Global Licensing Agreement With Abbott To Advance Blood-Based Alzheimer's Disease Testing 6/24/2026

    ALZpath Inc., the leader in blood test-based diagnostic solutions for Alzheimer's disease, today announced a licensing agreement with Abbott (NYSE: ABT), a global healthcare leader, to incorporate ALZpath's proprietary phosphorylated Tau 217 (pTau217) antibody into the development of an in vitro diagnostic (IVD) test for Alzheimer's disease.

  9. VERAXA Biotech Expands R&D Hub In Heidelberg As Innovative BiTAC™-TCE And ADC Programs Advance Towards Clinical Development 6/24/2026

    VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced that the Company has moved into additional laboratory space at its existing R&D site in Heidelberg, Germany, based on a previously signed long-term lease agreement.

  10. Quest Diagnostics Receives New York State Approval For Haystack MRD®, Broadening Patient Access To ctDNA Minimal Residual Disease Testing 6/24/2026

    Quest Diagnostics® (NYSE: DGX), a leading provider of diagnostic information services, today announced that the New York State Department of Health's (NYSDOH) Clinical Laboratory Evaluation Program (CLEP) has approved the company's Haystack MRD® test, a circulating tumor DNA (ctDNA) liquid biopsy test, for use in identifying residual or recurring disease in patients with a range of solid tumor cancers.